More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms

MADISON, N.J., March 12 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced today that it would need to conduct additional clinical studies to address questions from the Committee for Medicinal Products for Human Use (CHMP) regarding the risk-benefit p...

Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies

...age renal disease (ESRD). The dose should not be escalated in patients with moderate or severe renal impairment or ESRD. * Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with PRISTIQ. * Hyponatremia may occur as a result of treatment with SSRIs an...

Desvenlafaxine in Medical Technology

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

Pooled Findings Presented at 2007 APA Meeting Also Showed No Significant Impact on Weight for Desvenlafaxine Succinate COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ -- Findings from two separate pooled analyses - one examining the effect of desvenlafaxine succinate on anxious symptoms and...

New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder

- Data Presented at 2007 APA Meeting - COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ -- Data from four new studies examining safety and efficacy of desvenlafaxine succinate, a serotonin-norepinephrine reuptake inhibitor (SNRI) being studied as a potential treatment for adults with major d...

Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats

...verage within three days. Efficacy and Safety of desvenlafaxine Succinate for Treatment of Menopausal Vasomotor Sy...within one week of starting therapy. Efficacy of desvenlafaxine Succinate in the Treatment of Menopausal Vasomotor...week study period. A Placebo-Controlled Trial of desvenlafaxine Succinate and Tibolone for Menopausal Vasomotor Sy...

Desvenlafaxine in Biological Technology

Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo

COLLEGEVILLE, Pa., Oct. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), reported that new study data presented today at the 63rd Annual Meeting of the American Society for Reproductive Medicine (ASRM) showed that women who received 100 mg/day or 150 mg/da...

FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder

...e renal disease (ESRD). The dose should not be escalated in patients with moderate or severe renal impairment or ESRD. -- Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with PRISTIQ. Adverse Reactions -- The most commonly observed adverse re...

New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo

...ation of the Efficacy and Safety of Fixed Doses of desvenlafaxine Succinate at 50 mg and 100 mg in Outpatients with ...epression Rating Scale (HAM-D17). Patients in both desvenlafaxine groups started treatment at 50 mg/day. For the 100... AEs for the placebo, desvenlafaxine 50 mg/day and desvenlafaxine 100 mg/day groups were 3 percent, 3 percent and 7 ...